Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07053904Phase 1Enrolling By Invitation

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

Role: collaborator

NCT06883539Phase 1Recruiting

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Role: collaborator

NCT02289365Phase 2Unknown

Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Role: collaborator

All 3 trials loaded